内克塔治疗 NKTR 深 沪
等待开盘 10-06 09:30:00 美东时间
42.22
-1.360
-3.12%
华盛通- 最 高43.50
- 今 开43.50
- 成交量 202.93万股
- 最 低 41.35
- 昨 收 43.58
- 总市值 14.42亿
- 52周最高 109.00
- 市盈率 静 --
- 换手率 5.94%
- 52周最低 33.40
- 委 比 -88.89%
- 总股本 3414.30万
- 历史最高 1670.40
- 量 比 0.75
- 振 幅 4.93%
- 历史最低 6.189
- 每 手 1
- 风险率 13.22%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多美股大行评级 | 潜在涨幅405.62%！Inventiva(IVA)获Truist Securities上调目标价至18美元，维持"买入"评级
今日重点评级关注：Truist Securities：维持Inventiva"买入"评级，目标价从13美元升至18美元；富瑞：维持Sagimet Biosciences"买入"评级，目标价从25美元升至26美元
10-05 16:26
HC Wainwright & Co. Reiterates Buy on Nektar Therapeutics, Maintains $185 Price Target
HC Wainwright & Co. analyst Arthur He reiterates Nektar Therapeutics (NASDAQ:NKTR) with a Buy and maintains $185 price target.
10-02 19:29
Nektar shares long-term dermatology data on rezpegaldesleukin
Nektar Therapeutics ( ($NKTR) ) has provided an update. On October 1, 2026, Nek...
10-01 20:18
Nektar Wins $90 Million Verdict in Lilly Dispute
Nektar Therapeutics ( ($NKTR) ) has issued an announcement. In August 2023, Nek...
09-25 19:28
Nektar gains 5% as jury awards $90M plus interest in Lilly trial
Nektar Therapeutics (NKTR) on Friday said that a U.S. jury found Eli Lilly (LLY) liable for breaching an implied covenant of good faith and fair dealing in a dispute over their former collaboration on...
09-25 19:26
Lilly wins FDA nod for once-weekly insulin product, Onswik
Eli Lilly (LLY) on Thursday announced that the U.S. FDA approved its once-weekly basal insulin product, Onswik, for adults with type 2 diabetes to be used with diet and exercise for the control of hig...
09-24 19:07
美股大行评级 | 汽车地带绩后遭10家机构降目标价！最低看至3000美元；美光、微软、Meta齐获看多
今日重点评级关注：Leerink Partners：维持塞德斯医疗"跑赢大市"评级，目标价从70美元升至88美元；HC Wainwright & Co.：维持TriSalus Life Sciences"买入"评级，目标价从11美元升至12美元
09-24 16:10
Wedbush Maintains Neutral on Nektar Therapeutics, Lowers Price Target to $50
Wedbush analyst Martin Fan maintains Nektar Therapeutics (NASDAQ:NKTR) with a Neutral and lowers the price target from $80 to $50.
09-23 20:23
美股大行评级 | 戴尔、Adobe获大行上调目标价；甲骨文绩前目标价遭调低
今日重点评级关注：富国银行：维持Pyxis Oncology"超配"评级，目标价从12美元升至19美元；Oppenheimer：维持Opus Genetics"跑赢大市"评级，目标价从10美元升至20美元
09-10 15:00
